CY1118886T1 - Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης - Google Patents

Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης

Info

Publication number
CY1118886T1
CY1118886T1 CY20171100501T CY171100501T CY1118886T1 CY 1118886 T1 CY1118886 T1 CY 1118886T1 CY 20171100501 T CY20171100501 T CY 20171100501T CY 171100501 T CY171100501 T CY 171100501T CY 1118886 T1 CY1118886 T1 CY 1118886T1
Authority
CY
Cyprus
Prior art keywords
phenylsulfanyl
piperazine
dimethyl
phenyl
therapeutic uses
Prior art date
Application number
CY20171100501T
Other languages
English (en)
Inventor
Marianne Dragheim
Ioana Florea
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118886(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1118886T1 publication Critical patent/CY1118886T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση παρέχει νέες θεραπευτικές χρήσεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]-πιπεραζίνης και φαρμακευτικώς αποδεκτών αλάτων αυτής.
CY20171100501T 2010-08-23 2017-05-10 Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης CY1118886T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37588510P 2010-08-23 2010-08-23
DKPA201000739 2010-08-23
PCT/DK2011/050317 WO2012025123A1 (en) 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Publications (1)

Publication Number Publication Date
CY1118886T1 true CY1118886T1 (el) 2018-01-10

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100501T CY1118886T1 (el) 2010-08-23 2017-05-10 Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης

Country Status (30)

Country Link
US (4) US20130184291A1 (el)
EP (1) EP2608789B1 (el)
JP (1) JP5902169B2 (el)
KR (1) KR101816953B1 (el)
CN (1) CN103068389A (el)
AP (1) AP3583A (el)
AR (1) AR082501A1 (el)
AU (1) AU2011295465B8 (el)
BR (2) BR122020025600A2 (el)
CA (1) CA2807062C (el)
CL (1) CL2013000492A1 (el)
CO (1) CO6680652A2 (el)
CY (1) CY1118886T1 (el)
DK (1) DK2608789T3 (el)
ES (1) ES2625142T3 (el)
HR (1) HRP20170608T1 (el)
HU (1) HUE034155T2 (el)
IL (1) IL224371A (el)
LT (1) LT2608789T (el)
ME (1) ME02674B (el)
MX (1) MX349724B (el)
PL (1) PL2608789T3 (el)
PT (1) PT2608789T (el)
RS (1) RS55851B1 (el)
RU (1) RU2564666C2 (el)
SG (1) SG187649A1 (el)
SI (1) SI2608789T1 (el)
TW (1) TW201212918A (el)
WO (1) WO2012025123A1 (el)
ZA (1) ZA201301385B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
RU2018144248A (ru) 2016-07-01 2020-08-03 Х. Лундбекк А/С Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
ES2087463T3 (es) * 1991-11-18 1996-07-16 Lilly Industries Ltd Benzo(b)tiofen-2-carboxamidas para el tratamiento de trastornos del sistema nervioso central.
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
EP1322854A4 (en) 2000-10-02 2004-08-04 Rohr Inc APPARATUS, METHOD AND SYSTEM FOR REDUCING THE NOISE OF A GAS TURBINE
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CN101472906B (zh) 2006-06-16 2012-04-25 H.隆德贝克有限公司 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Also Published As

Publication number Publication date
EP2608789B1 (en) 2017-04-12
AU2011295465B2 (en) 2014-06-19
IL224371A (en) 2016-07-31
HUE034155T2 (en) 2018-01-29
AU2011295465A1 (en) 2013-02-07
CN103068389A (zh) 2013-04-24
US20190000836A1 (en) 2019-01-03
JP5902169B2 (ja) 2016-04-13
CA2807062A1 (en) 2012-03-01
ME02674B (me) 2017-06-20
PL2608789T3 (pl) 2017-09-29
HRP20170608T1 (hr) 2017-07-28
US20220370439A1 (en) 2022-11-24
AP2013006768A0 (en) 2012-03-31
MX2013001570A (es) 2013-03-21
US20210085674A1 (en) 2021-03-25
CO6680652A2 (es) 2013-05-31
EP2608789A1 (en) 2013-07-03
BR112013002194A2 (pt) 2016-05-31
KR101816953B1 (ko) 2018-01-09
CL2013000492A1 (es) 2013-06-07
AR082501A1 (es) 2012-12-12
PT2608789T (pt) 2017-05-26
RS55851B1 (sr) 2017-08-31
AU2011295465B8 (en) 2014-07-10
RU2564666C2 (ru) 2015-10-10
SI2608789T1 (sl) 2017-06-30
LT2608789T (lt) 2017-05-25
SG187649A1 (en) 2013-03-28
DK2608789T3 (en) 2017-05-15
TW201212918A (en) 2012-04-01
JP2013536206A (ja) 2013-09-19
US20130184291A1 (en) 2013-07-18
CA2807062C (en) 2018-07-31
AP3583A (en) 2016-02-09
RU2013112890A (ru) 2014-09-27
ZA201301385B (en) 2014-04-30
KR20130097162A (ko) 2013-09-02
ES2625142T3 (es) 2017-07-18
BR122020025600A2 (pt) 2021-01-05
MX349724B (es) 2017-08-10
WO2012025123A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
CY1117978T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a
CY1118886T1 (el) Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης
CY1118340T1 (el) Αναστολεις κινασης
EA201171287A1 (ru) Жидкие составы солей 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
UY34161A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen
CY1117424T1 (el) Βενζοδιαζεπινικος αναστολεας bromodomain
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
UY32649A (es) "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
CY1118323T1 (el) Ρυθμιστες του ηπατικου υποδοχεα χ
CL2011000481S1 (es) Aplicador para cuidado oral.
CY1123766T1 (el) Trans-4-{2-[4-(2,3- διχλωροφαινυλ)-πιπepazin-1-yλ]-aiθyλ}- ν,ν-διμεθυλκαρβαμοϋλ-κυκλοεξυλαμινη για θεραπεια πρωταρχικων αρνητικων συμπτωματων σχιζοφρενειας
EA201290116A1 (ru) Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
CY1118371T1 (el) Αναστολεις του iap
GB201209587D0 (en) Therapeutic compounds
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.
CL2009000257A1 (es) Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico.
UY34320A (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos.
CY1116334T1 (el) Νεο πολυμορφο
CY1115793T1 (el) Υγρα σκευασματα αλατων 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο)φαινυλο]πιπεραζινης
CY1115436T1 (el) Αναστολεις της κινασης p70 s6